Your browser doesn't support javascript.
loading
[Significance of combined use of anticoagulants and antiplatelet agents in the early stage after prosthetic valve replacement].
Toyohira, H; Nakamura, K; Kariyazono, H; Yamada, K; Moriyama, Y; Shimokawa, S; Saigenji, H; Taira, A.
Afiliação
  • Toyohira H; Second Department of Surgery, Faculty of Medicine Kagoshima University, Japan.
Kyobu Geka ; 48(9): 749-55, 1995 Aug.
Article em Ja | MEDLINE | ID: mdl-7564036
ABSTRACT
Patients who had undergone prosthetic valve replacement were treated with warfarin (anticoagulant) alone or in combination of ticlopidine (200 mg/day) or aspirin (81 mg/day) (anti-platelet agents). The study of blood coagulation factors and platelet aggregation were carried out with these cases. 1) The patients (n = 24) receiving warfarin for 21 days after prosthetic valve replacement revealed marked increases in PIVKA-II and vitamin K1-epoxide. The protein C activity was significantly lower than that before the operation. High levels of more than 5 ng/ml of TAT were found before operation and after warfarin administration for 21 days. 2) Warfarin did not affect platelet aggregation, whereas ticlopidine inhibited ADP-induced platelet aggregation and aspirin inhibited both collagen-induced and arachidonic acid-induced aggregation. In conclusion, combined use of anticoagulants and antiplatelet agents after prosthetic valve replacement will suppress not only the blood coagulation but also the platelet aggregation systems.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Varfarina / Ticlopidina / Próteses Valvulares Cardíacas / Inibidores da Agregação Plaquetária / Aspirina / Anticoagulantes Idioma: Ja Ano de publicação: 1995 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Varfarina / Ticlopidina / Próteses Valvulares Cardíacas / Inibidores da Agregação Plaquetária / Aspirina / Anticoagulantes Idioma: Ja Ano de publicação: 1995 Tipo de documento: Article